Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emcure PharmaceuticalsNSE:EMCURE -3.02%41 Days Payable is 153.71 as of Jun. 2026, which is 7% below its 10-year median of 165.79. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 924 Drug Manufacturers companies, Emcure Pharmaceuticals ranks better than 77.16% on this metric.
The historical rank and industry rank for Emcure Pharmaceuticals's Days Payable or its related term are showing as below:
NSE:EMCURE'
s Days Payable Range Over the Past 10 Years
Min: 155.26 Med: 165.79 Max: 177.77
Current: 155.26
During the past 6 years, Emcure Pharmaceuticals's highest Days Payable was 177.77. The lowest was 155.26. And the median was 165.79.
NSE:EMCURE's Days Payable is ranked better than 77.16% of 924
companies
in the Drug Manufacturers industry
Industry Median: 89.105
vs NSE:EMCURE: 155.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emcure Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emcure Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emcure Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Emcure Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Emcure Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emcure Pharmaceuticals (NSE:EMCURE) has a Days Payable of 153.71 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emcure Pharmaceuticals and its competitors. This is near median its historical median of 165.79. Over the past decade, Emcure Pharmaceuticals' Days Payable has ranged from 155.26 to 177.77. According to the industry distribution chart, Emcure Pharmaceuticals ranks #211 out of 924 companies in the Drug Manufacturers industry, placing it in the top 22.8%.
Is Emcure Pharmaceuticals' Days Payable too high?
Emcure Pharmaceuticals' current Days Payable of 153.71 is near median its 10-year median of 165.79. Over the past 10 years, this metric has ranged from a low of 155.26 to a high of 177.77. The Drug Manufacturers industry median Days Payable is 89.11. Emcure Pharmaceuticals' value of 153.71 is 72.5% above this industry median. Based on the distribution chart, Emcure Pharmaceuticals ranks #211 out of 924 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Emcure Pharmaceuticals ranks #211 out of 924 companies for Days Payable. This places Emcure Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 89.11. Emcure Pharmaceuticals' value of 153.71 is 72.5% above this benchmark. Historically, Emcure Pharmaceuticals' own Days Payable has ranged from 155.26 to 177.77 over the past decade. While the company's 10-year median is 165.79 vs. the industry median of 89.11, Emcure Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.11, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emcure Pharmaceuticals's current Days Payable of 153.71 is 72.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Emcure Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emcure Pharmaceuticals's current Days Payable is 153.71, which is near median its own 10-year median of 165.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Days Payable of 153.71. The current Days Payable is 153.71, which is near median its 10-year median of 165.79 and 72.5% above the Drug Manufacturers industry median of 89.11. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Days Payable is 153.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score
Get the complete analysis for NSE:EMCURE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EMCURE has been successfully added to your 
